.png){kind=icon}
.png){kind=icon}
Return
PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting
.png){kind=icon}
OA
AI
DOI：10.1002/cpt.3044.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP2D6 gene locus and a comprehensive summary of structural variation. CYP2D6 contributes to the metabolism of numerous drugs and, thus, genetic variation in its gene impacts drug efficacy and safety. To accurately predict a patient's CYP2D6 phenotype, testing must include structural variants including gene deletions, duplications, hybrid genes, and combinations thereof. This tutorial offers a comprehensive overview of CYP2D6 structural variation, terms, and definitions, a review of methods suitable for their detection and characterization, and practical examples to address the lack of standards to describe CYP2D6 structural variants or any other pharmacogene. This PharmVar tutorial offers practical guidance on how to detect the many, often complex, structural variants, as well as recommends terms and definitions for clinical and research reporting. Uniform reporting is not only essential for electronic health record-keeping but also for accurate translation of a patient's genotype into phenotype which is typically utilized to guide drug therapy.
Keywords:
COPY-NUMBER VARIATION
PHARMACOGENETICS IMPLEMENTATION CONSORTIUM
DROPLET-DIGITAL PCR
ULTRARAPID METABOLIZERS
GENE DUPLICATION
LOCUS
DEBRISOQUINE
PHENOTYPE
IDENTIFICATION
GENOTYPE
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
C
IF:
5.5
Papers:
8.6K
Citations:
1.9W
View more organizations